Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2224777/is-adicet-bio-acet-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2224777
Feb 12, 2024 - Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
0
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
https://www.zacks.com/stock/news/2221181/bio-rad-laboratories-bio-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221181
Feb 05, 2024 - Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.
0
Intelligent Bio Solutions Expects Higher Q2 Revenue, Stock Up In Pre-Market
https://www.rttnews.com/story.aspx?Id=3421577
Feb 02, 2024 - Medical technology company Intelligent Bio Solutions Inc. (INBS), Friday announced that it expects higher revenue for its second quarter. The preliminary outlook is mainly due to increased demand for its drug screening solution, and expansion into new global markets.
0
SPAC Semper Paratus shareholders okay merger with Tevogen Bio
https://seekingalpha.com/news/4061494-spac-semper-paratus-shareholders-okay-merger-with-tevogen-bio?source=feed_sector_healthcare
Feb 01, 2024 - SPAC Semper Paratus Acquisition Corp. (LGST) shareholders have approved a merger deal with immunotherapy developer Tevogen Bio (TVGN). Read more here.
0
Tourmaline Bio director discloses purchase of stake worth $3.25M
https://seekingalpha.com/news/4061462-tourmaline-bio-director-discloses-purchase-of-stake-worth-325m?source=feed_sector_healthcare
Feb 01, 2024 - This article discusses insider trading at Tourmaline Bio (TRML), with its director Mark McDade acquiring 100,000 company shares for $3.25 million.
0
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
0
Tourmaline Bio looks to raise cash through a public offering
https://seekingalpha.com/news/4058138-tourmaline-bio-looks-to-raise-cash-through-a-public-offering?source=feed_sector_healthcare
Jan 24, 2024 - Tourmaline Bio announces proposed public offering of common stock. Underwriters may purchase additional shares.
0
Annovis Bio, Kura Oncology among other healthcare movers
https://seekingalpha.com/news/4057908-annovis-bio-kura-oncology-among-other-healthcare-movers?source=feed_sector_healthcare
Jan 24, 2024 - Read about the top gainers and losers in the healthcare sector.
0
Adicet Bio announces pricing of public offering
https://seekingalpha.com/news/4057425-adicet-bio-announces-pricing-of-public-offering?source=feed_sector_healthcare
Jan 23, 2024 - Adicet Bio announces the pricing of its public offering, with expected gross proceeds of $85.2M, to close on January 25, 2024.
0
Adicet Bio stock sinks on proposed public offering
https://seekingalpha.com/news/4057105-adicet-bio-stock-sinks-on-proposed-public-offering?source=feed_sector_healthcare
Jan 22, 2024 - Adicet Bio starts underwritten public offering, causing its stock to plummet by 15.3%.
0